WASHINGTON, DC – November 3, 2014 – Bruker Corporation (NASDAQ: BRKR) announced today, the evolution of their maXis™ line of ultrahigh-resolution quadrupole time-of-flight (UHR-qTOF) mass spectrometers, bringing industry-leading resolution and mass accuracy to the liquid chromatography, time-of-flight MS market space. The system, announced at IBC’s 18th annual Well Characterized Biologicals Conference, is designed to deliver outstanding resolution and mass accuracy which allows for unambiguous identification of the mono-isotopic mass peak of both the light and heavy chains of monoclonal antibodies for example. In addition, this level of performance also provides scientists confident detection and identification of modifications hard to detect at the protein level, such as deamidation.
"The maXis II system delivers the fastest time-to-success for life science researchers and across a broad range of applications from the in-depth identification and characterization of biopharmaceuticals and small molecule pharmaceuticals, to bottom-up proteomics and proteoform screening.” said Dr. Bob Galvin, Vice President of Bruker’s Biopharmaceutical Business Unit. “Additionally, the system is well suited to research in the metabolomics, food safety, and forensic and toxicology screening markets as well."
The maXis II™ – UHR-qTOF Mass Spectrometer
The new maXis II system is the latest flagship instrument in Bruker’s unique TOF mass spectrometry product line, allowing the simultaneous analysis of small molecules and megadalton proteins on one analytical platform. The system delivers:
- Industry-leading (>80,000) Full-Sensitivity Resolution (FSR) at UPLC acquisition speeds thus enabling Bruker’s unique and industry acknowledged True Isotopic Pattern spectral acquisition. This allows for the identification of the mono-isotopic mass peak of both the light and heavy chains of monoclonal antibodies or, when linked to Smart Formula 3D provides unambiguous elemental formula determination for the pharmaceutical and related industries
- A High Mass Option (HMO) yieldingnative spray MS capabilities provides enhanced analytical performance levels, particularly suited for biopharmaceutical and pharmaceutical challenges, like the analysis of megadalton protein complexes and determination of antibody drug conjugates (ADCs)
- The Electron Transfer Dissociation (ETD) option provides a powerful additional MS/MS fragmentation technique for the sequence analysis of intact proteins including monoclonal antibody subunits. The ETD MS/MS fragmentation technique is complimentary to collision induced dissociation (CID) MS/MS, yielding greater sequence coverage for proteins and providing additional capabilities to the new system
The maXis II mass spectrometer is available immediately. Please contact your local Bruker Sales Representative for a quote.
About Bruker Corporation
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis. For more information about Bruker Corporation (NASDAQ: BRKR), please visit www.bruker.com.
T: +1 978 663 3660 ext.1212
Vice President of Investor Relations, Bruker Corporation
T: +1 978 663 3660 ext.1479